# Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

> **NCT04091204** · PHASE2 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 200 (estimated)

## Conditions studied

- BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

## Interventions

- **DRUG:** Olaparib tablets

## Key facts

- **NCT ID:** NCT04091204
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-04
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04091204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04091204, "Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04091204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*